CN105985318A - 作为t790变异抑制剂的嘧啶衍生物 - Google Patents

作为t790变异抑制剂的嘧啶衍生物 Download PDF

Info

Publication number
CN105985318A
CN105985318A CN201510083925.1A CN201510083925A CN105985318A CN 105985318 A CN105985318 A CN 105985318A CN 201510083925 A CN201510083925 A CN 201510083925A CN 105985318 A CN105985318 A CN 105985318A
Authority
CN
China
Prior art keywords
straight
branched alkyl
substituted
pyrimidine derivatives
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510083925.1A
Other languages
English (en)
Chinese (zh)
Inventor
王能辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ningbo Wonder Pharmaceutical Technology Co Ltd
Original Assignee
Ningbo Wonder Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ningbo Wonder Pharmaceutical Technology Co Ltd filed Critical Ningbo Wonder Pharmaceutical Technology Co Ltd
Priority to CN201510083925.1A priority Critical patent/CN105985318A/zh
Priority to PCT/CN2016/073818 priority patent/WO2016127949A1/fr
Publication of CN105985318A publication Critical patent/CN105985318A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201510083925.1A 2015-02-15 2015-02-15 作为t790变异抑制剂的嘧啶衍生物 Pending CN105985318A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201510083925.1A CN105985318A (zh) 2015-02-15 2015-02-15 作为t790变异抑制剂的嘧啶衍生物
PCT/CN2016/073818 WO2016127949A1 (fr) 2015-02-15 2016-02-15 Dérivé de pyrimidine utilisé comme inhibiteur agissant sur la mutation t790

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510083925.1A CN105985318A (zh) 2015-02-15 2015-02-15 作为t790变异抑制剂的嘧啶衍生物

Publications (1)

Publication Number Publication Date
CN105985318A true CN105985318A (zh) 2016-10-05

Family

ID=56614151

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510083925.1A Pending CN105985318A (zh) 2015-02-15 2015-02-15 作为t790变异抑制剂的嘧啶衍生物

Country Status (2)

Country Link
CN (1) CN105985318A (fr)
WO (1) WO2016127949A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106243044A (zh) * 2016-06-30 2016-12-21 浙江大学 含卤代丙烯酰胺侧链的嘧啶类衍生物及制备和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110526915B (zh) * 2018-05-25 2022-02-01 首药控股(北京)股份有限公司 一种间变性淋巴瘤激酶抑制剂的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975249B2 (en) * 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
JP5957003B2 (ja) * 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
CN104860921A (zh) * 2014-02-24 2015-08-26 宁波文达医药科技有限公司 作为t790变异抑制剂的嘧啶衍生物
CN104860922A (zh) * 2014-02-24 2015-08-26 宁波文达医药科技有限公司 作为间变性淋巴瘤激酶抑制剂的嘧啶衍生物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106243044A (zh) * 2016-06-30 2016-12-21 浙江大学 含卤代丙烯酰胺侧链的嘧啶类衍生物及制备和应用

Also Published As

Publication number Publication date
WO2016127949A1 (fr) 2016-08-18

Similar Documents

Publication Publication Date Title
US10016408B2 (en) Chemokine CXCR4 receptor modulators and uses related thereto
CN105315259B (zh) 吡啶胺基嘧啶衍生物、其制备方法及应用
JP2021050233A (ja) ｃ−Ｍｅｔモジュレーターおよびその使用
CN108290864B (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
CN101360499B (zh) 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途
CN103965114B (zh) 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
CN107056772A (zh) 基于cereblon配体诱导BET降解的双功能分子及其制备和应用
KR20080006614A (ko) 증식 질환의 치료에 유용한 ｈｓｐ90 억제제인2-아미노-퀴나졸린-5-온
CN105985323A (zh) 新型表皮生长因子受体抑制剂及其应用
CN105705493B (zh) 喹唑啉衍生物、其制备方法、药物组合物和应用
CN105753817A (zh) 一类取代氮杂环衍生物及其应用
CN107245075B (zh) 2,4,6-三取代吡啶并[3,4-d]嘧啶类化合物及其盐和应用
CN105218561B (zh) 稠合嘧啶环衍生物、其制备方法及应用
WO2011153942A1 (fr) Dérivé de cyanoquinoline
CA2980478A1 (fr) Compositions et methodes pour inhiber les kinases
AU2013326850B2 (en) Novel compounds, their preparation and their uses
CN104557913B (zh) 吡啶并嘧啶类化合物，其制备方法和用途
CN105985318A (zh) 作为t790变异抑制剂的嘧啶衍生物
US3301855A (en) Derivatives of 4-nu-(2-nu, nu-dimethylaminolower alkyl)-amino quinazoline
JP6965432B2 (ja) キノリンおよびナフチリジンの誘導体および組成物
CN106554318A (zh) 氘代二苯基氨基嘧啶化合物
WO2018036539A1 (fr) Cristal de sel de dérivé de quinazoline
WO2016206551A1 (fr) Application d'inhibiteur de la protéine src dans un médicament pour la prévention et/ou le traitement de la maladie d'alzheimer
WO2001038306A9 (fr) Nouveaux derives de la 3-nitropyridine et preparations pharmaceutiques les contenant
CN104860921A (zh) 作为t790变异抑制剂的嘧啶衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161005